Repligen (NASDAQ:RGEN) PT Raised to $200.00

Repligen (NASDAQ:RGEN) had its target price hoisted by JPMorgan Chase & Co. from $190.00 to $200.00 in a report issued on Wednesday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biotechnology company’s stock.

RGEN has been the subject of several other research reports. UBS Group lowered their price objective on shares of Repligen from $205.00 to $185.00 and set a buy rating for the company in a research note on Wednesday. Royal Bank of Canada reissued an outperform rating and issued a $190.00 price target on shares of Repligen in a research report on Wednesday. Deutsche Bank Aktiengesellschaft raised shares of Repligen from a hold rating to a buy rating and reduced their price target for the company from $180.00 to $155.00 in a research report on Wednesday, June 26th. Guggenheim initiated coverage on shares of Repligen in a research report on Tuesday, June 18th. They issued a neutral rating for the company. Finally, Stephens reissued an overweight rating and issued a $170.00 price target on shares of Repligen in a research report on Tuesday, July 30th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average target price of $189.57.

Repligen Stock Down 2.4 %

Repligen stock opened at $161.67 on Wednesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.24 and a current ratio of 6.65. Repligen has a 52-week low of $110.45 and a 52-week high of $211.13. The firm has a 50 day moving average price of $134.92 and a two-hundred day moving average price of $166.00. The firm has a market cap of $9.06 billion, a price-to-earnings ratio of 646.71, a PEG ratio of 5.98 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The firm had revenue of $154.07 million during the quarter, compared to analyst estimates of $154.11 million. During the same quarter last year, the business earned $0.53 EPS. The company’s revenue was down 3.2% compared to the same quarter last year. Equities analysts predict that Repligen will post 1.44 EPS for the current year.

Insiders Place Their Bets

In other Repligen news, VP Ralf Kuriyel sold 4,465 shares of Repligen stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total transaction of $739,716.55. Following the transaction, the vice president now directly owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, VP Ralf Kuriyel sold 4,465 shares of Repligen stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the sale, the vice president now directly owns 19,261 shares in the company, valued at approximately $3,190,969.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Martin D. Madaus bought 1,615 shares of the stock in a transaction dated Friday, June 14th. The shares were acquired at an average price of $124.94 per share, for a total transaction of $201,778.10. Following the completion of the purchase, the director now directly owns 4,613 shares in the company, valued at $576,348.22. The disclosure for this purchase can be found here. Insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

Hedge funds have recently made changes to their positions in the business. Norges Bank bought a new stake in Repligen in the 4th quarter valued at about $48,208,000. Bank of New York Mellon Corp raised its stake in Repligen by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after acquiring an additional 237,884 shares during the period. Conestoga Capital Advisors LLC raised its stake in Repligen by 26.7% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock valued at $119,363,000 after acquiring an additional 199,322 shares during the period. Public Employees Retirement Association of Colorado raised its stake in Repligen by 448.0% in the 4th quarter. Public Employees Retirement Association of Colorado now owns 112,863 shares of the biotechnology company’s stock valued at $20,293,000 after acquiring an additional 92,268 shares during the period. Finally, Brown Capital Management LLC raised its stake in Repligen by 5.8% in the 4th quarter. Brown Capital Management LLC now owns 1,525,064 shares of the biotechnology company’s stock valued at $274,207,000 after acquiring an additional 83,416 shares during the period. 97.64% of the stock is currently owned by institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.